MX2017009955A - Anticuerpos orientados a un antigeno o basado en galactano de k. pneumoniae. - Google Patents
Anticuerpos orientados a un antigeno o basado en galactano de k. pneumoniae.Info
- Publication number
- MX2017009955A MX2017009955A MX2017009955A MX2017009955A MX2017009955A MX 2017009955 A MX2017009955 A MX 2017009955A MX 2017009955 A MX2017009955 A MX 2017009955A MX 2017009955 A MX2017009955 A MX 2017009955A MX 2017009955 A MX2017009955 A MX 2017009955A
- Authority
- MX
- Mexico
- Prior art keywords
- pneumoniae
- galactane
- antigen
- galactan
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Gram-negative bacteria
- C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Gram-negative bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- G01N2333/26—Klebsiella (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15155448 | 2015-02-17 | ||
| PCT/EP2015/075583 WO2016131503A1 (en) | 2015-02-17 | 2015-11-03 | Antibodies targeting a galactan-based o-antigen of k. pneumoniae |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017009955A true MX2017009955A (es) | 2017-10-19 |
Family
ID=52469764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009955A MX2017009955A (es) | 2015-02-17 | 2015-11-03 | Anticuerpos orientados a un antigeno o basado en galactano de k. pneumoniae. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11466074B2 (https=) |
| EP (1) | EP3259287A1 (https=) |
| JP (2) | JP6987638B2 (https=) |
| KR (1) | KR20170122726A (https=) |
| CN (1) | CN107371365B (https=) |
| AU (1) | AU2015383632B2 (https=) |
| BR (1) | BR112017017553A2 (https=) |
| CA (1) | CA2973134A1 (https=) |
| IL (1) | IL253920B2 (https=) |
| MX (1) | MX2017009955A (https=) |
| RU (2) | RU2021131224A (https=) |
| WO (1) | WO2016131503A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017017553A2 (pt) * | 2015-02-17 | 2018-05-08 | Arsanis Biosciences Gmbh | ?anticorpos direcionados contra um antígeno o baseado em galactano de k. pneumoniae, método de produção, preparação farmacêutica ou diagnóstica, método de diagnóstico, método de identificação, ácido nucleico isolado, célula hospedeira e invólucro de expressão? |
| KR20190077306A (ko) | 2016-08-05 | 2019-07-03 | 메디뮨 엘엘씨 | 항-o2 항체 및 이의 용도 |
| SG11201903063UA (en) * | 2016-10-19 | 2019-05-30 | Medimmune Llc | Anti-o1 antibodies and uses thereof |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| CN120775040A (zh) * | 2021-08-25 | 2025-10-14 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别肺炎克雷伯菌o1抗原的抗体及其应用 |
| EP4445911A4 (en) | 2021-12-06 | 2025-10-22 | Beijing Solobio Genetechnology Co Ltd | BISPECIFIC ANTIBODY THAT BINDS SPECIFICALLY TO KLEBSIELLA PNEUMONIAE O1 AND O2 ANTIGENS AND COMPOSITION |
| CN118620072A (zh) * | 2023-12-27 | 2024-09-10 | 上海博钒生物科技有限公司 | 一种肺炎克雷伯菌多糖单克隆抗体、其杂交瘤细胞株及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US20050112141A1 (en) * | 2000-08-30 | 2005-05-26 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| EA013564B1 (ru) * | 2000-08-03 | 2010-06-30 | Терапеутик Хьюман Поликлоналз Инк. | Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| EP3124497B1 (en) | 2007-09-14 | 2020-04-15 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| KR102318383B1 (ko) | 2010-07-16 | 2021-10-27 | 아디맵 엘엘씨 | 항체 라이브러리 |
| BR112017017553A2 (pt) * | 2015-02-17 | 2018-05-08 | Arsanis Biosciences Gmbh | ?anticorpos direcionados contra um antígeno o baseado em galactano de k. pneumoniae, método de produção, preparação farmacêutica ou diagnóstica, método de diagnóstico, método de identificação, ácido nucleico isolado, célula hospedeira e invólucro de expressão? |
-
2015
- 2015-11-03 BR BR112017017553A patent/BR112017017553A2/pt not_active Application Discontinuation
- 2015-11-03 CN CN201580075698.6A patent/CN107371365B/zh not_active Expired - Fee Related
- 2015-11-03 KR KR1020177021389A patent/KR20170122726A/ko not_active Abandoned
- 2015-11-03 US US15/551,813 patent/US11466074B2/en active Active
- 2015-11-03 CA CA2973134A patent/CA2973134A1/en active Pending
- 2015-11-03 EP EP15790526.6A patent/EP3259287A1/en not_active Withdrawn
- 2015-11-03 MX MX2017009955A patent/MX2017009955A/es unknown
- 2015-11-03 RU RU2021131224A patent/RU2021131224A/ru unknown
- 2015-11-03 RU RU2017132168A patent/RU2759950C2/ru active
- 2015-11-03 JP JP2017543737A patent/JP6987638B2/ja not_active Expired - Fee Related
- 2015-11-03 WO PCT/EP2015/075583 patent/WO2016131503A1/en not_active Ceased
- 2015-11-03 AU AU2015383632A patent/AU2015383632B2/en not_active Ceased
-
2017
- 2017-08-09 IL IL253920A patent/IL253920B2/en unknown
-
2021
- 2021-11-30 JP JP2021194395A patent/JP2022058341A/ja not_active Withdrawn
-
2022
- 2022-08-16 US US17/820,082 patent/US20230220055A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170122726A (ko) | 2017-11-06 |
| JP2018508208A (ja) | 2018-03-29 |
| BR112017017553A2 (pt) | 2018-05-08 |
| US20180066041A1 (en) | 2018-03-08 |
| CN107371365A (zh) | 2017-11-21 |
| CA2973134A1 (en) | 2016-08-25 |
| AU2015383632A1 (en) | 2017-07-27 |
| CN107371365B (zh) | 2022-01-11 |
| RU2021131224A (ru) | 2021-11-03 |
| IL253920B (en) | 2022-10-01 |
| IL253920B2 (en) | 2023-02-01 |
| US20230220055A1 (en) | 2023-07-13 |
| EP3259287A1 (en) | 2017-12-27 |
| JP6987638B2 (ja) | 2022-01-05 |
| AU2015383632B2 (en) | 2021-10-21 |
| RU2759950C2 (ru) | 2021-11-19 |
| WO2016131503A1 (en) | 2016-08-25 |
| IL253920A0 (en) | 2017-10-31 |
| US11466074B2 (en) | 2022-10-11 |
| RU2017132168A3 (https=) | 2019-06-11 |
| RU2017132168A (ru) | 2019-03-18 |
| JP2022058341A (ja) | 2022-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017009955A (es) | Anticuerpos orientados a un antigeno o basado en galactano de k. pneumoniae. | |
| CL2021000630A1 (es) | Métodos para producir un anticuerpo anti-c5 (divisional de la solicitud no. 201701585) | |
| CL2019000100A1 (es) | Anticuerpos contra tim3 y suso de los mismos. | |
| MX2016012124A (es) | Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos. | |
| CY1122804T1 (el) | Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα) | |
| BR112019002579A2 (pt) | anticorpos biespecíficos fab monovalentes, assimétricos e tandem | |
| CL2019003657A1 (es) | Anticuerpos que se unen específicamente a cd38 útiles para mejorar una respuesta inmune en un paciente. (divisional solicitud 201703275) | |
| CO2017007673A2 (es) | Anticuerpos anti-cd47 | |
| CL2017003261A1 (es) | Factor xi anticuerpos y métodos de uso | |
| SV2018005659A (es) | Anticuerpos agonistas que se unen especificamente a cd40 humanos y metodos de uso | |
| JOP20170004B1 (ar) | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته | |
| CO2018000809A2 (es) | Anticuerpos para cd40 | |
| BR112018014615A2 (pt) | composições de anticorpo para ror1 e métodos relacionados | |
| CL2016002547A1 (es) | Anticuerpos contra her2 biespecíficos | |
| EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
| CL2016001979A1 (es) | Métodos de tratamiento de enfermedad de alzheimer. | |
| MX2018005015A (es) | Anticuerpos dirigidos a un antigeno-o de manano de la k. pneumoniae. | |
| MX2018016362A (es) | Formulaciones de anticuerpo anti-cd19. | |
| CU24446B1 (es) | Un anticuerpo monoclonal humanizado que se une a tau | |
| BR112018070948A2 (pt) | anticorpos anti-psma e utilização dos mesmos | |
| JO3791B1 (ar) | تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6 | |
| MX2022015250A (es) | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. | |
| WO2015164392A8 (en) | Novel anti-rnf43 antibodies and methods of use | |
| CY1124949T1 (el) | Αντισωμα | |
| IL286467A (en) | Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof |